Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

摘要: Background Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing multiple myeloma (MM) must be overcome. Cytometry societies such as the International Clinical Society and European for Cell Analysis recognize a strong need to establish minimally acceptable requirements recommendations perform complex testing. Methods A group of 11 cytometrists currently performing FC MM using different instrumentation, panel designs (≥ 6-color) analysis software compared procedures their respective reviewed literature propose consensus guideline on flow-MRD reporting MM. Results/Conclusion Consensus guidelines support i) use minimum five initial gating parameters (CD38, CD138, CD45, forward, sideward light scatter) within same aliquot accurate identification total plasma cell compartment; ii) potentially aberrant phenotypic markers report antigen expression pattern neoplastic cells being reduced, normal or increased, when reference immunophenotype (obtained instrument parameters); iii) percentage bone marrow plus percentages both compartment, over cells. Consensus current future MRD analyses should target lower limit detection 0.001%, ideally quantification which requires at least 3 × 106 5 measured, respectively. © 2015